Ayvakit

Blueprint boosts Ayvakit peak sales estimate to $2B as key rare disease expansion accelerates
Fierce Pharma
Thu, 02/15/24 - 11:13 am
Blueprint Medicines
Ayvakit
earnings
Blueprint's Ayvakit picks up long-awaited FDA approval in indolent systemic mastocytosis
Fierce Pharma
Mon, 05/22/23 - 10:07 pm
Blueprint Medicines
Ayvakit
FDA
indolent systemic mastocytosis
systemic mastocytosis
Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label
Endpoints
Mon, 02/27/23 - 10:03 am
Blueprint Medicines
FDA
Ayvakit
systemic mastocytosis
Blueprint gears up for Ayvakit expansion, with blockbuster sales on the line
Fierce Pharma
Fri, 02/17/23 - 11:21 am
Blueprint Medicines
Ayvakit
FDA
systemic mastocytosis
Blueprint drug succeeds in rare disease study important to its market prospects
BioPharma Dive
Wed, 08/17/22 - 10:55 am
Blueprint Medicines
systemic mastocytosis
clinical trials
Ayvakit
Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines
BioSpace
Thu, 06/17/21 - 10:55 am
Blueprint Medicines
Ayvakit
MCL
systemic mastocytosis
FDA
Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer
Endpoints
Tue, 09/22/20 - 10:17 pm
Blueprint Medicines
Roche
FDA
Ayvakit
FDA approval tracker: several early decisions in May
EP Vantage
Wed, 06/3/20 - 10:24 am
FDA
Deciphera
Qinlock
Blueprint Medicines
Ayvakit
Eli Lilly
Retevmo
Bristol-Myers Squibb
Opdivo
Yervoy
Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer
Fierce Pharma
Mon, 05/18/20 - 10:59 pm
Blueprint Medicines
Deciphera
FDA
GIST
Ayvakit
Qinlock
After a PhIII failure, the FDA delivers Blueprint an expected CRL
Endpoints
Fri, 05/15/20 - 10:37 am
Blueprint Medicines
FDA
complete response letter
Ayvakit
gastrointestinal stromal tumors
Blueprint’s voyage ends in disaster
EP Vantage
Wed, 04/29/20 - 10:45 am
Blueprint Medicines
Ayvakit
clinical trials
The crucial data readouts coming soon for small biotechs
EP Vantage
Thu, 04/23/20 - 12:37 pm
clinical trials
Akebia
Blueprint Medicines
Genfit
TG Therapeutics
vadadustat
Ayvakit
elafibranor
Blueprint gets first approval as FDA backs stomach cancer drug
Pharmaforum
Fri, 01/10/20 - 10:20 am
Blueprint Medicines
FDA
Ayvakit
stomach cancer